肺部肿瘤的基因治疗。
Gene therapy for lung neoplasms.
机构信息
Division of Pulmonary, Allergy & Critical Care Medicine, University of Pennsylvania, 3400 Spruce Street, Philadelphia, PA 19104, USA.
出版信息
Clin Chest Med. 2011 Dec;32(4):865-85. doi: 10.1016/j.ccm.2011.08.006. Epub 2011 Oct 7.
Abstract
Both advanced-stage lung cancer and malignant pleural mesothelioma are associated with a poor prognosis. Advances in treatment regimens for both diseases have had only a modest effect on their progressive course. Gene therapy for thoracic malignancies represents a novel therapeutic approach and has been evaluated in several clinical trials. Strategies have included induction of apoptosis, tumor suppressor gene replacement, suicide gene expression, cytokine-based therapy, various vaccination approaches, and adoptive transfer of modified immune cells. This review considers the clinical results, limitations, and future directions of gene therapy trials for thoracic malignancies.
摘要
晚期肺癌和恶性胸膜间皮瘤均预后不良。两种疾病的治疗方案的进步仅对其进展过程产生了适度的影响。胸恶性肿瘤的基因治疗代表了一种新的治疗方法，并已在几项临床试验中进行了评估。策略包括诱导细胞凋亡、肿瘤抑制基因替代、自杀基因表达、细胞因子为基础的治疗、各种疫苗接种方法以及修饰免疫细胞的过继转移。本文回顾了胸恶性肿瘤基因治疗试验的临床结果、局限性和未来方向。
相似文献
1
Gene therapy for lung neoplasms.肺部肿瘤的基因治疗。
Clin Chest Med. 2011 Dec;32(4):865-85. doi: 10.1016/j.ccm.2011.08.006. Epub 2011 Oct 7.
2
Gene therapy for mesothelioma and lung cancer.间皮瘤和肺癌的基因治疗。
Am J Respir Cell Mol Biol. 2010 Apr;42(4):385-93. doi: 10.1165/rcmb.2010-0026RT. Epub 2010 Feb 16.
3
Mesothelioma: an inviting but challenging target for gene therapy.间皮瘤：基因治疗中一个诱人但具有挑战性的靶点。
Am J Respir Cell Mol Biol. 2010 Apr;42(4):383-4. doi: 10.1165/rcmb.2010-0071ED.
4
Intracavitary 'T4 immunotherapy' of malignant mesothelioma using pan-ErbB re-targeted CAR T-cells.使用泛表皮生长因子受体（ErbB）重新靶向嵌合抗原受体（CAR）T细胞对恶性间皮瘤进行腔内“T4免疫疗法”
Cancer Lett. 2017 May 1;393:52-59. doi: 10.1016/j.canlet.2017.02.015. Epub 2017 Feb 20.
5
New therapeutic strategies for malignant pleural mesothelioma.恶性胸膜间皮瘤的新治疗策略
Biochem Pharmacol. 2017 Jan 1;123:8-18. doi: 10.1016/j.bcp.2016.07.012. Epub 2016 Jul 16.
6
Pilot and Feasibility Trial Evaluating Immuno-Gene Therapy of Malignant Mesothelioma Using Intrapleural Delivery of Adenovirus-IFNα Combined with Chemotherapy.评估使用腺病毒 - 干扰素α胸腔内注射联合化疗对恶性间皮瘤进行免疫基因治疗的先导性和可行性试验
Clin Cancer Res. 2016 Aug 1;22(15):3791-800. doi: 10.1158/1078-0432.CCR-15-2133. Epub 2016 Mar 11.
7
Immune checkpoint inhibitors in malignant pleural mesothelioma: promises and challenges.恶性胸膜间皮瘤中的免疫检查点抑制剂：前景与挑战
Expert Rev Anticancer Ther. 2016 Jul;16(7):673-5. doi: 10.1080/14737140.2016.1191951. Epub 2016 May 30.
8
Chemotherapy delivered after viral immunogene therapy augments antitumor efficacy via multiple immune-mediated mechanisms.病毒免疫基因治疗后进行化疗通过多种免疫介导的机制增强抗肿瘤疗效。
Mol Ther. 2010 Nov;18(11):1947-59. doi: 10.1038/mt.2010.159. Epub 2010 Aug 3.
9
Intrapleural immunotherapy: An update on emerging treatment strategies for pleural malignancy.胸膜内免疫疗法：胸膜恶性肿瘤新兴治疗策略的最新进展
Clin Respir J. 2019 May;13(5):272-279. doi: 10.1111/crj.13010. Epub 2019 Mar 24.
10
Regional delivery of mesothelin-targeted CAR T cell therapy generates potent and long-lasting CD4-dependent tumor immunity.间皮素靶向嵌合抗原受体T细胞疗法的局部递送可产生强大且持久的CD4依赖性肿瘤免疫。
Sci Transl Med. 2014 Nov 5;6(261):261ra151. doi: 10.1126/scitranslmed.3010162.
引用本文的文献
1
Bronchoscopic intratumoural therapies for non-small cell lung cancer.经支气管镜肿瘤内治疗非小细胞肺癌。
Eur Respir Rev. 2020 Jun 16;29(156). doi: 10.1183/16000617.0028-2020. Print 2020 Jun 30.
2
Overexpression of MCPH1 inhibits uncontrolled cell growth by promoting cell apoptosis and arresting the cell cycle in S and G2/M phase in lung cancer cells.MCPH1的过表达通过促进细胞凋亡以及使肺癌细胞的细胞周期停滞在S期和G2/M期来抑制细胞的失控生长。
Oncol Lett. 2016 Jan;11(1):365-372. doi: 10.3892/ol.2015.3857. Epub 2015 Nov 4.
3
Therapeutic properties of a vector carrying the HSV thymidine kinase and GM-CSF genes and delivered as a complex with a cationic copolymer.携带单纯疱疹病毒胸苷激酶和粒细胞-巨噬细胞集落刺激因子基因并与阳离子共聚物形成复合物递送的载体的治疗特性
J Transl Med. 2015 Mar 4;13:78. doi: 10.1186/s12967-015-0433-0.
4
Safety and efficacy of suicide gene therapy with adenosine deaminase 5-fluorocytosine silmutaneously in in vitro cultures of melanoma and retinal cell lines.腺嘌呤脱氨酶-5-氟胞嘧啶自杀基因联合治疗对黑色素瘤和视网膜细胞系体外培养的安全性和疗效。
J Cancer. 2014 Apr 17;5(5):368-81. doi: 10.7150/jca.9147. eCollection 2014.
5
Suicide Gene Therapy for Cancer - Current Strategies.癌症的自杀基因疗法——当前策略
J Genet Syndr Gene Ther. 2013 Aug 9;4. doi: 10.4172/2157-7412.1000139.
6
MEN1 gene replacement therapy reduces proliferation rates in a mouse model of pituitary adenomas.MEN1 基因替代疗法可降低垂体腺瘤小鼠模型中的增殖率。
Cancer Res. 2012 Oct 1;72(19):5060-8. doi: 10.1158/0008-5472.CAN-12-1821. Epub 2012 Aug 21.
7
Natural diterpenes from coffee, cafestol and kahweol induce apoptosis through regulation of specificity protein 1 expression in human malignant pleural mesothelioma.咖啡中的天然二萜类化合物——咖啡醇和卡韦醇通过调节人恶性胸膜间皮瘤中特异性蛋白 1 的表达诱导细胞凋亡。
J Biomed Sci. 2012 Jun 26;19(1):60. doi: 10.1186/1423-0127-19-60.
本文引用的文献
1
A trial of intrapleural adenoviral-mediated Interferon-α2b gene transfer for malignant pleural mesothelioma.腺病毒介导的α2b 干扰素基因转移治疗恶性胸膜间皮瘤的临床试验。
Am J Respir Crit Care Med. 2011 Dec 15;184(12):1395-9. doi: 10.1164/rccm.201103-0554CR. Epub 2011 Jun 3.
2
Approval of provenge seen as first step for cancer treatment vaccines.普罗文奇的获批被视为癌症治疗疫苗的第一步。
J Natl Cancer Inst. 2010 Aug 4;102(15):1108-10. doi: 10.1093/jnci/djq295. Epub 2010 Jul 28.
3
Improved survival with ipilimumab in patients with metastatic melanoma.Ipilimumab 改善转移性黑色素瘤患者的生存。
N Engl J Med. 2010 Aug 19;363(8):711-23. doi: 10.1056/NEJMoa1003466. Epub 2010 Jun 5.
4
A phase I trial of repeated intrapleural adenoviral-mediated interferon-beta gene transfer for mesothelioma and metastatic pleural effusions.一项针对间皮瘤和转移性胸腔积液的重复胸膜内腺病毒介导干扰素-β基因转移的 I 期试验。
Mol Ther. 2010 Apr;18(4):852-60. doi: 10.1038/mt.2009.309. Epub 2010 Jan 12.
5
[Clinical research on recombinant human Ad-p53 injection combined with cisplatin in treatment of malignant pleural effusion induced by lung cancer].重组人 Ad-p53 注射液联合顺铂治疗肺癌所致恶性胸腔积液的临床研究
Ai Zheng. 2009 Dec;28(12):1324-7. doi: 10.5732/cjc.009.10149.
6
Requirements for control of B-cell lymphoma by NK cells.自然杀伤细胞控制 B 细胞淋巴瘤的需求。
Eur J Immunol. 2010 Feb;40(2):494-504. doi: 10.1002/eji.200939937.
7
Long-term outcome of EBV-specific T-cell infusions to prevent or treat EBV-related lymphoproliferative disease in transplant recipients.移植受者中预防或治疗 EBV 相关淋巴增殖性疾病的 EBV 特异性 T 细胞输注的长期结果。
Blood. 2010 Feb 4;115(5):925-35. doi: 10.1182/blood-2009-08-239186. Epub 2009 Oct 30.
8
Adenovirus-mediated wild-type p53 gene transfer in combination with bronchial arterial infusion for treatment of advanced non-small-cell lung cancer, one year follow-up.腺病毒介导的野生型p53基因转移联合支气管动脉灌注治疗晚期非小细胞肺癌，一年随访
J Zhejiang Univ Sci B. 2009 May;10(5):331-40. doi: 10.1631/jzus.B0820248.
9
Expanding the repertoire of Modified Vaccinia Ankara-based vaccine vectors via genetic complementation strategies.通过基因互补策略扩大基于安卡拉痘苗病毒的改良疫苗载体的种类。
PLoS One. 2009;4(5):e5445. doi: 10.1371/journal.pone.0005445. Epub 2009 May 6.
10
Phase II trial of Belagenpumatucel-L, a TGF-beta2 antisense gene modified allogeneic tumor vaccine in advanced non small cell lung cancer (NSCLC) patients.Belagenpumatucel-L（一种转化生长因子-β2反义基因修饰的异体肿瘤疫苗）用于晚期非小细胞肺癌（NSCLC）患者的II期试验。
Cancer Gene Ther. 2009 Aug;16(8):620-4. doi: 10.1038/cgt.2009.15. Epub 2009 Mar 13.
Zotero 插件